Form 4: Vir Biotechnology Director Sells Shares Under 10b5-1 Plan

Vir Biotechnology Director Vicki L. Sato sold 22,000 shares of common stock for a weighted average price of $5.9265 per share, pursuant to a Rule 10b5-1 trading plan.

Summary

• Vicki L. Sato, a Director of Vir Biotechnology, Inc. (VIR), reported the sale of 22,000 shares of common stock.
• The transaction occurred on January 2, 2026.
• The shares were sold at a weighted average price of $5.9265 per share.
• The sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Ms. Sato on March 27, 2025.
• The individual transaction prices ranged from $5.84 to $6.09 per share.
• Following this transaction, Ms. Sato beneficially owns 1,166,391 shares of Vir Biotechnology common stock.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to an insider reducing their stake, but this is significantly mitigated by the fact that the sale was pre-planned under a Rule 10b5-1 plan, suggesting it was not based on new, adverse information.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which indicates the transaction was scheduled in advance and not based on new, undisclosed material information.

Negatives

• A Director reduced their direct ownership stake in the company by selling 22,000 shares.

Risks

• Insider selling, even when pre-planned, can sometimes be perceived negatively by the market, potentially leading to questions about management's confidence in future prospects.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a routine disclosure of an insider transaction and does not provide specific insights into broader industry trends or competitive landscape.

Corporate Governance

Stakeholder Impact

• Shareholders may interpret the director's sale as a signal, though the 10b5-1 plan mitigates concerns about opportunistic selling.

Key Dates

Recommendation

While insider selling can be a negative signal, the fact that this transaction was executed under a pre-arranged Rule 10b5-1 trading plan reduces its immediate bearish implications. It suggests a planned diversification or liquidity event rather than a reaction to new, undisclosed negative company news. Investors should monitor future insider activity and company performance, but this single, pre-planned sale does not warrant a strong buy or sell recommendation at this time.

Keywords

Vir Biotechnology, VIR, Vicki L. Sato, Insider Trading, Form 4, Stock Sale, Director, 10b5-1 Plan, Equity Transaction